Status:
UNKNOWN
Meropenem vs Cefotaxime as Empirical Treatment of SBP
Lead Sponsor:
Assiut University
Conditions:
Spontaneous Bacterial Peritonitis
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
We aimed to evaluate whether meropenem is superior to cefotaxime for treatment of SBP empirically.
Detailed Description
Ascites is the most frequent complication of cirrhosis and represents a significant change for the patient because the impact on mortality and quality of life is important. Spontaneous bacterial peri...
Eligibility Criteria
Inclusion
- Liver cirrhosis patients with ascites Ascitic fluid PMN cell count \>250/mm3 Age: 18:80
Exclusion
- : history of abdominal surgery within 4 weeks, secondary peritonitis, tuberculous peritonitis, Malignant tumor, patients who use hormones or immunosuppressants, AIDS patients.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2024
Estimated Enrollment :
286 Patients enrolled
Trial Details
Trial ID
NCT05427747
Start Date
January 1 2023
End Date
February 1 2024
Last Update
June 22 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.